Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Open Access
- 21 November 1991
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 325 (21), 1468-1475
- https://doi.org/10.1056/nejm199111213252103
Abstract
Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined.Keywords
This publication has 36 references indexed in Scilit:
- Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group.Circulation, 1990
- Xamoterol in severe heart failureThe Lancet, 1990
- A Comparison of Oral Milrinone, Digoxin, and Their Combination in the Treatment of Patients with Chronic Heart FailureNew England Journal of Medicine, 1989
- Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hopeJournal of the American College of Cardiology, 1988
- Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.Circulation, 1987
- Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.Circulation, 1985
- Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.Circulation, 1984
- Inotropic and vasodilator effects of amrinone on isolated human tissueCardiovascular Research, 1984
- Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart FailureNew England Journal of Medicine, 1983
- Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure.Circulation, 1982